MODULATION OF FETAL HEMOGLOBIN IN SICKLE CELL ANEMIA

Abstract

A partial understanding of the pathophysiology of sickle cell disease has suggested one means of treatment—increasing the distribution and concentration of fetal hemoglobin in sickle erythrocytes. Although this can be accomplished clinically with drugs like hydroxyurea, a complete understanding of the molecular and cellular basis of fetal hemoglobin regulation may suggest new and better ways of attaining this goal.